NONOF Company Profile and Key Details

Average 10-day trading volume of 62.95 thousand shares is below the 3-month average of 153.21 thousand, indicating normal recent market interest.

Novo Nordisk A/S earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -8.07%. The prior quarter beat by -1.16%. Over the last six quarters, Apple has recorded several small beats. These include 0.78% in November 06, 2024.

Novo Nordisk A/S last paid a dividend of 1.73 per share, this equals a trailing yield of roughly 7.24%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $99.53. This means the shares are trading below this model’s fair value.

Novo Nordisk A/S (OTC:NONOF) closed at $38.28 USD, gaining $0.53 (1.40%) from the previous close of $37.75. The stock is currently mid-range between its 52-week high and low $35.51 and $92.42. With a market capitalization of about $170.08 billion, Novo Nordisk A/S is classified as a large-cap and shows lower-than-market volatility (beta ~0.40). Key stats such as the average daily volume over the past year has been around 169.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Bagsvaerd, None, Novo Nordisk A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Maziar Mike Doustdar, the company employs approximately 77,406 people and listed since May 07, 2010. Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.

Our AI price prediction model suggests that Novo Nordisk A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Novo Nordisk A/S trading at a premium to the broader market with a P/E of 9.85.

Novo Nordisk A/S trades at a P/E ratio of 9.85, slightly below the S&P 500 average, with a price-to-sales ratio of 3.27 and a price-to-book ratio of 5.21 trading at moderately above to book value. The P/FCF stands at 17.94, also above market averages.